Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24483838 | 0.92 | HDAC1 (0.35) | LMNAGAATP53PARP1 | |
| SCHEMBL24173421 | 0.91 | ALDH1A1 (0.36) | LMNASMN1; SMN2GAATP53PARP1 | |
| SCHEMBL22845478 | 0.91 | LMNA (0.36) | LMNASMN1; SMN2TSHRCASP1PRKAA2 | |
| SCHEMBL22845445 | 0.90 | MAPT (0.35) | TP53 | |
| SCHEMBL22845380 | 0.89 | MAPT (0.35) | LMNAPOLBGAATP53 | |
| SCHEMBL26842658 | 0.89 | MAPT (0.35) | LMNASMN1; SMN2POLBKMT2AGAA | |
| SCHEMBL22845425 | 0.89 | MTHFD2 (0.33) | LMNASMN1; SMN2GAATP53 | |
| SCHEMBL22845500 | 0.87 | MTHFD2 (0.35) | LMNAGAATP53 | |
| SCHEMBL22830614 | 0.87 | PRKAA2 (0.34) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL22845339 | 0.86 | P2RX7 (0.35) | LMNAPOLBKMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | LMNA 1680/4885SMN1; SMN2 1114/4885TSHR 2105/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | LMNA 1680/4885SMN1; SMN2 1114/4885TSHR 2105/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | LMNA 1680/4885SMN1; SMN2 1114/4885TSHR 2105/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | LMNA 1680/4885SMN1; SMN2 1114/4885TSHR 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.